

Accepted Manuscript

Review

Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections

Erik De Clercq

PII: S0006-2952(17)30709-8
DOI: <https://doi.org/10.1016/j.bcp.2017.11.023>
Reference: BCP 12973

To appear in: *Biochemical Pharmacology*

Received Date: 23 October 2017
Accepted Date: 28 November 2017

Please cite this article as: E. De Clercq, Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections, *Biochemical Pharmacology* (2017), doi: <https://doi.org/10.1016/j.bcp.2017.11.023>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Revised manuscript BCP-D-17-01030

Biochemical Pharmacology

Diamond Jubilee Special Issue

Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections[§]

Erik De Clercq*

KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research,

Herestraat 49, B-3000 Leuven, Belgium

*Tel: + 32 16 379020

E-mail address: erik.declercq@kuleuven.be

[§]This review article is dedicated to the memory of Dr. Antonín Holý, co-discoverer of tenofovir, who died on 16 July 2012.

Download English Version:

<https://daneshyari.com/en/article/8523842>

Download Persian Version:

<https://daneshyari.com/article/8523842>

[Daneshyari.com](https://daneshyari.com)